Companies Dominating the Anthrax Treatment Market
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Integrated Bio Therapeutics Inc.
- Sun Pharmaceutical Industries Ltd.
- Bayer AG
- Zydus Group
- GC Biopharma, corp.
- BlueWillow Biologics.
- Emergent BioSolutions
- ARISTO Pharmaceuticals Private Limited
Browse Key Market Insights with Data Illustration:
In the News
- Emergent BioSolutions received approval from the US Food and Drug Administration (FDA) for, Cyfendus an adjuvant-packed adsorbed version of the anthrax vaccination approved for usage in post-exposure prophylaxis in adults between the ages of 18 and 65.
- GC Biopharma, corp. applied to obtain approval from the Korean Ministry of Food and Drug Safety (MFDS) for, "GC1109", an anthrax vaccine developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), that contains protective antigen (PA), and will be the first recombinant anthrax vaccine in history if it is authorized to aid in the preparation for a possible bioterrorism attack and the ensuing national emergency.
